Management of hepatitis C-infected liver transplant recipients at large North American centres: Changes in recent years

Clinical Transplantation

Volumn 20, Issue 1, 2006, Pages 1-9

  Khalili, Mandana ^a   Vardanian, Andrew J ^a   Hamerski, Chris M ^a   Wang, Rou ^a   Bacchetti, Peter ^a   Roberts, John P ^a   Terrault, Norah A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allograft rejection; Antiviral therapy; Immuno suppression; Retransplantation; Survey

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISONE; RIBAVIRIN; TSUKUBAENOLIDE;

ACUTE GRAFT REJECTION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONTROLLED STUDY; GRAFT FAILURE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; NORTH AMERICA; PRIORITY JOURNAL; REOPERATION; REVIEW; TREATMENT INDICATION;

CANADA; GRAFT REJECTION; HEALTH CARE SURVEYS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER FAILURE; LIVER TRANSPLANTATION; PHYSICIAN'S PRACTICE PATTERNS; RECURRENCE; UNITED STATES;

EID: 33644799276     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00449.x     Document Type: Review

References (42)

1. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002: 122: 889.
2. Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000: 32: 673.
3. Sanchez-Fueyo A, Restrepo JC, Quinto L et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002: 73: 56.
4. Prieto M, Berenguer M, Rayon J et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999: 29: 250.
5. Gane E, Portmann B, Naoumov N et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996: 334: 815.
6. Feray C, Caccamo L, Alexander GJ et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999: 117: 619.
7. Neumann U, Berg T, Bahra M et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004: 41: 830.
8. Berenguer M, Prieto M, Rayon JM et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000: 32: 852.
9. Rosen HR, Madden JP, Martin P. A model to predict survival following liver retransplantation. Hepatology 1999: 29: 365.
10. Neff G, O 'Brien C, Nery J et al. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl 2004: 10: 1497.
11. Watt KD, Lyden ER, McCashland TM. Poor survival after liver retransplantation: Is hepatitis C to blame? Liver Transpl 2003: 9: 1019.
12. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002: 8 (10 Suppl. 1): S14.
13. Terrault NA. Hepatitis C virus and liver transplantation. Semin Gastrointest Dis 2000: 11: 96.
14. Wiesner R, Sorrell M, Villamil F, International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003: 9: S1.
15. Nelson DR, Soldevila-Pico C, Reed A et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001: 7: 1064.
16. Neuhaus P, Clavien PA, Kittur D et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002: 8: 132.
17. Jain A, Eghtesad B, Venkataramanan R et al. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl 2002: 8: 1007.
18. Narayanan Menon KV, Poterucha JJ, El-Amin OM et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: Lessons on tolerability and efficacy. Liver Transpl 2002: 8: 623.
19. Shakil AO, McGuire B, Crippin J et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002: 36: 1253.
20. Armstrong G, Alter M, McQuillan G, Margolis H. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States. Hepatology 2000: 31: 777.
21. Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy. Gastroenterology 2004: 127 (5 Suppl. 1): S261.
22. Sebagh M, Rifai K, Feray C et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 2003: 37: 1293.
23. Berenguer M, Rayon JM, Prieto M et al. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl 2001: 7: 790.
24. Mueller A, Platz K, Berg T et al. Long-term follow-up in hepatitis C patients with respect to immunosuppression. Transpl Proc 1996: 28: 3241.
25. Zervos X, Weppler D, Fragulidis G et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998: 65: 1044.
26. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999: 6 (4 Suppl. 1): S107. S107
27. Ghobrial RM, Farmer DG, Baquerizo A et al. Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-centre experience. Ann Surg 1999: 229: 824 (discussion 31-3).
28. Wiesner R, Rabkin J, Klintmalm G et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001: 7: 442.
29. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003: 75: 1396.
30. Brillanti S, Vivarelli M, De Ruvo N et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002: 8: 884.
31. Belli L, Alberti A, Vangeli M, Airoldi A, Pinzello G. Tapering off steroids three months after liver transplantation is not detrimental for hepatitis C virus disease recurrence. Liver Transpl 2003: 9: 201.
32. Sheiner P, Schwartz M, Mor E et al. Severe and multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995: 21: 30.
33. Rosen H, Shackleton C, Higa L et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997: 92: 1453.
34. Firpi R, Abdelmalek M, Soldevila-Pico C et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002: 8: 1000.
35. Samuel D, Bizollon T, Feray C et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2003: 124: 642.
36. Stravitz R, Shiffman M, Sanyal A et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004: 10: 850.
37. Giostra E, Kullak-Ublick G, Keller W et al. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 2004: 17: 169.
38. Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998: 66: 1612.
39. Yoo HY, Maheshwari A, Thuluvath PJ. Retransplantation of liver: Primary graft nonfunction and hepatitis C virus are associated with worse outcome. Liver Transpl 2003: 9: 897.
40. Markmann JF, Markowitz JS, Yersiz H et al. Long-term survival after retransplantation of the liver. Ann Surg 1997: 226: 408 (discussion 18-20).
41. Doyle HR, Morelli F, McMichael J et al. Hepatic Retransplantation - an analysis of risk factors associated with outcome. Transplantation 1996: 61: 1499.
42. Facciuto M, Heidt D, Guarrera J et al. Retransplantation for late liver graft failure: Predictors of mortality. Liver Transpl 2000: 6: 174.